THRA and neoplasm: There was a higher breast cancer-specific mortality among women with low, compared with high, THRα-2 tumor expression, HR 1.38 (95% CI 0.96–1.99) for all of follow-up and HR 1.52 (95% CI 1.03–2.24) for the period 0–15 years.